NCT05275478 2026-04-15
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
Phase 1/2 Terminated
Tango Therapeutics, Inc.
Hutchmed
Imugene Limited
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Oslo University Hospital
Peking University